XtalPi is an AI-driven biotechnology company focused on drug discovery and materials science. It uses artificial intelligence, quantum physics, and robotics to accelerate pharmaceutical R&D and provide digital R&D solutions.
UpMarket does not offer XtalPi shares. This page covers XtalPi's history before it went public.
XtalPi became a public company on June 13, 2024 and trades on the Hong Kong Stock Exchange as 2228. UpMarket does not offer XtalPi shares. This page covers XtalPi's valuation and funding history before it went public.
XtalPi listed on the Hong Kong Stock Exchange under the ticker 2228 on June 13, 2024.
See how XtalPi's private-market valuation changed across funding rounds before it went public.
See reported funding rounds and revenue figures on this page, with their sources.
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
| Date | Round | PPS (split-adj.) | Valuation |
|---|---|---|---|
| Mar 2018 | Series B | ||
| 2016 | Pre-Series B |
XtalPi announced an oversubscribed Series C round of $318.8 million in September 2020, co-led by SoftBank Vision Fund 2, PICC Capital, and Morningside. The company said the capital would support its AI drug discovery and development platform across pharmaceutical research workflows.
XtalPi describes itself as an AI drug discovery company leveraging artificial intelligence, quantum physics, and robotics to accelerate pharmaceutical research. Its website says the mission is to fuse physics and machine learning for faster, smarter drug development.
Forge Global describes XtalPi as a pharmaceutical technology company reinventing drug research and development with its Intelligent Digital Drug Discovery and Development platform. Forge also lists a last known valuation of about $2 billion as of January 2026, suggesting sizable market investor interest.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
Browse the directory →UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
Yes. XtalPi became a public company on June 13, 2024 and trades on the Hong Kong Stock Exchange under the ticker 2228. UpMarket does not offer XtalPi shares.
XtalPi's share price is set on the public market under the ticker 2228. The prices shown on this page are historical private-market prices from before it went public.
No. XtalPi is now a public company and UpMarket does not offer its shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
XtalPi is now publicly traded, so its shares can be bought and sold on the Hong Kong Stock Exchange and their price can change significantly. Review XtalPi's public filings and consult a financial advisor before investing. UpMarket does not offer XtalPi shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
XtalPi became a public company on June 13, 2024, so shares held before the listing can generally be sold on the public market once any lock-up period ends. The exact terms depend on how the shares are held, for example directly or through a fund.
UpMarket does not offer XtalPi shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
XtalPi's valuation is now set by its public share price on the Hong Kong Stock Exchange. The figures on this page show its valuation history before it went public.
XtalPi is an AI drug discovery and materials science company using artificial intelligence, quantum physics, and robotics to accelerate pharmaceutical R&D, and it raised $318.8 million in Series C funding to scale that platform. XtalPi is now a public company, and UpMarket does not offer its shares.